PubMed Health⌕ Search

PubMed · 6895759

New developments in the vitamin D endocrine system.

Abstract

Vitamin D must be altered first by 25-hydroxylation in the liver and subsequently by 1-hydroxylation in the kidney in order to stimulate intestinal calcium transport, bone calcium mobilization, intestinal phosphate transport, and renal tubular reabsorption of calcium. Other pathways of vitamin D metabolism are described, and evidence is presented which indicates that only 25- and 1-hydroxylation pathways are activation mechanisms. The 1 alpha-hydroxylation step is regulated by the need for calcium and the need for phosphorus. The vitamin D hormone, 1,25-dihydroxyvitamin D3, appears to act in target tissues by virtue of interacting with a receptor appearing in the nucleus and eliciting transcription of specific genetic information that codes for calcium and phosphorus transport proteins. Diseases of calcium and phosphorus metabolism in which there is a disturbance of the vitamin D endocrine system and the use of the vitamin D metabolites are discussed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H F DeLuca. 1982. New developments in the vitamin D endocrine system.. https://pubmed.ncbi.nlm.nih.gov/6895759/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Chronic kidney disease-mineral-bone disorder: a new paradigm.

Disturbances in mineral and bone metabolism are prevalent in chronic kidney disease (CKD) and an important cause of morbidity, decreased quality of life, and extraskeletal calcification that have been associated with increased cardiovascular mortality. These disturbances have traditionally been termed renal osteodystrophy and classified on the basis of bone biopsy. Kidney Disease: Improving Global Outcomes (KDIGO) recently sponsored a Controversies Conference to evaluate this definition. The recommendations were that (1) the term renal osteodystrophy be used exclusively to define alterations in bone morphology associated with CKD and (2) the term CKD-mineral and bone disorder (CKD-MBD) be used to describe the broader clinical syndrome that develops as a systemic disorder of mineral and bone metabolism as a result of CKD. CKD-MBD is manifested by an abnormality of any one or a combination of the following: laboratory-abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism; bone-changes in bone turnover, mineralization, volume, linear growth, or strength; and calcification-vascular or other soft-tissue calcification. The pathogenesis and clinical manifestations of these components of CKD-MBD are described in detail in this issue of Advances in Chronic Kidney Disease.

Bone Diseases, Metabolic↗